Per Magne Ueland

Per Magne Ueland

Auto-generated profile, based on publicly available information

Per Magne Ueland

Bevital AS, Bergen, Norway

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 1998 in Annual Review of Medicine
Verified
Journal Article
Closed access
HRH. Refsum
H. Refsum
PUP. M. Ueland
P. M. Ueland
ONO. Nygård
O. Nygård
SVS. E. Vollset
S. E. Vollset
An elevated level of total homocysteine (tHcy) in blood, denoted hyperhomocysteinemia, is emerging as a prevalent and strong risk factor for atherosclerotic vascular disease in the coronary, cerebral, and peripheral vessels, and for arterial and venous thromboembolism. The basis for these conclusions is data from about 80 clinical and epidemiological studies including more than 10,000 patients. Elevated tHcy confers a graded risk with no threshold, is independent of but may enhance the effect of the conventional risk factors, and seems to be a particularly strong predictor of cardiovascular mortality. Hyperhomocysteinemia is attributed to commonly occurring genetic and acquired factors including deficiencies of folate and vitamin B12. Supplementation with B-vitamins, in particular with folic acid, is an efficient, safe, and inexpensive means to reduce an elevated tHcy level. Studies are now in progress to establish whether such therapy will reduce cardiovascular risk.

6 May 2010 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
PDF file
PUPer Magne Ueland
Per Magne Ueland

1 February 2017 in Molecular Aspects of Medicine
Verified
Journal Article
Closed access
PUPer Magne Ueland
Per Magne Ueland
AMAdrian McCann
Adrian McCann
ØMØivind Midttun
Øivind Midttun
AUArve Ulvik
Arve Ulvik

1 April 2001 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
PUPer Magne Ueland
Per Magne Ueland
SHSteinar Hustad
Steinar Hustad
JSJørn Schneede
Jørn Schneede
HRHelga Refsum
Helga Refsum
SVStein Emil Vollset
Stein Emil Vollset

1 August 2000 in The American Journal of Clinical Nutrition
Verified
Journal Article
Open access
PDF file
PUPer M Ueland
Per M Ueland
HRHelga Refsum
Helga Refsum
SBShirley Aa Beresford
Shirley Aa Beresford
SVStein Emil Vollset
Stein Emil Vollset
Elevated plasma total homocysteine (tHcy) is a risk factor for occlusive cardiovascular disease (CVD). This concept is based on the observations of premature vascular disease in patients with homocystinuria, the relation between tHcy and both clinical CVD as well as preclinical atherosclerotic disease, the relation between tHcy in children and CVD in their parents or relatives, and reduction in CVD or surrogate endpoints after tHcy-lowering intervention with B vitamins. Plausible mechanisms include the in vivo interference with nitric oxide–dependent reactive vasodilatation. Some observations have raised questions about tHcy as a risk factor. 1) Some prospective studies showed a weak relation or no relation between tHcy and CVD. 2) Several traditional risk factors are associated with tHcy and may confound the relation between tHcy and CVD. 3) tHcy is related to renal function, and hyperhomocysteinemia may reflect early nephrosclerosis. 4) The C677T transition of the methylenetetrahydrofolate reductase gene causes a moderate increase in tHcy but no or only minor increased CVD risk. However, the strength of some of these arguments can be questioned because there is increasing evidence that tHcy is a proximate risk factor provoking the acute event, it strongly interacts with traditional risk factors, and it may predict CVD or death in patients with chronic renal failure. Furthermore, the studies of the C677T polymorphism lack statistical power, and the TT genotype may even modulate CVD risk independently of homocysteine. Thus, only placebo-controlled intervention studies with tHcy-lowering B vitamins and clinical endpoints can provide additional valid arguments for the debate over whether tHcy is a causal CVD risk factor.

17 July 2015 in Annual Review of Nutrition
Verified
Journal Article
Closed access
PUPer Magne Ueland
Per Magne Ueland
AUArve Ulvik
Arve Ulvik
LRLuisa Rios-Avila
Luisa Rios-Avila
ØMØivind Midttun
Øivind Midttun
JGJesse Gregory
Jesse Gregory
Measures of B6 status are categorized as direct biomarkers and as functional biomarkers. Direct biomarkers measure B6 vitamers in plasma/serum, urine and erythrocytes, and among these plasma pyridoxal 5′-phosphate (PLP) is most commonly used. Functional biomarkers include erythrocyte transaminase activities and, more recently, plasma levels of metabolites involved in PLP-dependent reactions, such as the kynurenine pathway, one-carbon metabolism, transsulfuration (cystathionine), and glycine decarboxylation (serine and glycine). Vitamin B6 status is best assessed by using a combination of biomarkers because of the influence of potential confounders, such as inflammation, alkaline phosphatase activity, low serum albumin, renal function, and inorganic phosphate. Ratios between substrate-products pairs have recently been investigated as a strategy to attenuate such influence. These efforts have provided promising new markers such as the PAr index, the 3-hydroxykynurenine:xanthurenic acid ratio, and the oxoglutarate:glutamate ratio. Targeted metabolic profiling or untargeted metabolomics based on mass spectrometry allow the simultaneous quantification of a large number of metabolites, which are currently evaluated as functional biomarkers, using data reduction statistics.